Health
Regeneron Shares Head for Worst Month Since 2019 on Legal Ruling
- Big blow came Monday with decision opening door to Amgen drug
- Stock is still up about 19% in 2024, outpacing industry index
This article is for subscribers only.
Regeneron Pharmaceuticals Inc. shares are headed for their biggest monthly drop since mid-2019 after a legal setback that opens the door to an early launch of a competing therapy to the drugmaker’s blockbuster eye treatment, Eylea.
The stock is down about 12% in September and is also the worst performer in the S&P 500 Index this week. The shares edged higher on Friday after news that the company received approval in the US for a separate drug, and they’re still up about 19% in 2024.